Abeona Stock Analysis

ABEO
 Stock
  

USD 3.04  0.08  2.70%   

The latest Abeona Therapeutics price slide could raise concerns from institutional investors as the firm is trading at a share price of 3.04 on 48,256 in volume. The company executives were unable to exploit market volatilities in August. However, diversifying your overall positions with Abeona Therapeutics can protect your principal portfolio during market swings. The stock standard deviation of daily returns for 90 days investing horizon is currently 6.14. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Abeona Therapeutics partners.
Please continue to Trending Equities.
  
The Abeona Therapeutics stock analysis report makes it easy to digest most publicly released information about Abeona Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Abeona Stock analysis module also helps to analyze the Abeona Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Abeona Stock Analysis Notes

About 22.0% of the company shares are held by institutions such as insurance companies. The book value of Abeona Therapeutics was presently reported as 1.07. The company recorded a loss per share of 0.91. Abeona Therapeutics had not issued any dividends in recent years. The entity had 25.00 - 1.00 split on the 24th of October 2014. Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York. Abeona Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 90 people. For more info on Abeona Therapeutics please contact Timothy Miller at 646 813 4701 or go to https://www.abeonatherapeutics.com.

Abeona Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Abeona Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Abeona Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Abeona Therapeutics generated a negative expected return over the last 90 days
Abeona Therapeutics has high historical volatility and very poor performance
Abeona Therapeutics is unlikely to experience financial distress in the next 2 years
The company reported the previous year's revenue of 3.35 M. Net Loss for the year was (89.72 M) with loss before overhead, payroll, taxes, and interest of (299 K).
Abeona Therapeutics currently holds about 31.32 M in cash with (65.77 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.33, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Latest headline from MacroaxisInsider: Acquisition by Wuchterl Donald A of 13400 shares of Abeona Therapeutics subject to Rule 16b-3

Abeona Therapeutics Upcoming and Recent Events

Earnings reports are used by Abeona Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Abeona Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report23rd of March 2022
Next Financial Report17th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End23rd of March 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Abeona Therapeutics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Abeona Therapeutics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Abeona Therapeutics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Abeona Therapeutics specific information freely available to individual and institutional investors to make a timely investment decision.
17th of August 2022
Submission of Matters to a Vote of Security Holders
View
11th of August 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
20th of July 2022
Financial Statements and Exhibits. Other Events
View
30th of June 2022
Financial Statements and Exhibits. Amendments to Articles of Incorporation or Bylaws; and/or Change in Fiscal Year. Material Modifications to Rights of Security Holders
View
14th of June 2022
Submission of Matters to a Vote of Security Holders
View
19th of May 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
View
17th of May 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Entry into a Material Definitive Agreement
View
13th of May 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View

Abeona Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Abeona Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Abeona Therapeutics backward and forwards among themselves. Abeona Therapeutics' institutional investor refers to the entity that pools money to purchase Abeona Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Adage Capital Partners Gp LlcCommon SharesM1.7 M
Renaissance Technologies LlcCommon Shares2.4 M499 K
Vanguard Group IncCommon Shares2.3 M472 K
Knoll Capital Management LlcCommon Shares2.2 M461 K
Blackrock IncCommon Shares1.4 M291 K
D E Shaw Co IncCommon Shares1.2 M256 K
Geode Capital Management LlcCommon Shares898.5 K187 K
Note, although Abeona Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Abeona Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 439.85 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Abeona Therapeutics's market, we take the total number of its shares issued and multiply it by Abeona Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (36.37) % which means that it has lost $36.37 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (142.61) %, meaning that it created substantial loss on money invested by shareholders. Abeona Therapeutics management efficiency ratios could be used to measure how well abeona therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 30th of September, Abeona Therapeutics shows the mean deviation of 4.87, and Risk Adjusted Performance of (0.09). Abeona Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to analyze and collect data for nineteen technical drivers for Abeona Therapeutics, which can be compared to its rivals. Please confirm Abeona Therapeutics jensen alpha, and the relationship between the coefficient of variation and potential upside to decide if Abeona Therapeutics is priced correctly, providing market reflects its regular price of 3.04 per share. Given that Abeona Therapeutics has jensen alpha of (0.38), we suggest you to validate Abeona Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.

Abeona Therapeutics Price Movement Analysis

The output start index for this execution was thirty with a total number of output elements of thirty-one. The Moving Average is predictive technique used to analyze Abeona Therapeutics price data points by creating a series of averages of different subsets of Abeona Therapeutics entire price series.
.

Abeona Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Abeona Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Abeona Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Abeona Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Wuchterl Donald A 2 days ago via Macroaxis 
Acquisition by Wuchterl Donald A of 13400 shares of Abeona Therapeutics subject to Rule 16b-3
Omalley Brendan M over a week ago via Macroaxis 
Payment of 479 shares by Omalley Brendan M of Abeona Therapeutics subject to Rule 16b-3
Vazzano Joseph Walter over two months ago via Macroaxis 
Acquisition by Vazzano Joseph Walter of 12000 shares of Abeona Therapeutics subject to Rule 16b-3
Seshadri Vishwas over three months ago via Macroaxis 
Payment of 81525 shares by Seshadri Vishwas of Abeona Therapeutics subject to Rule 16b-3
Mark Alvino over three months ago via Macroaxis 
Sale by Mark Alvino of 35000 shares of Abeona Therapeutics
Todd Wider over three months ago via Macroaxis 
Exercise or conversion by Todd Wider of 100000 shares of Abeona Therapeutics subject to Rule 16b-3
Vazzano Joseph Walter over six months ago via Macroaxis 
Acquisition by Vazzano Joseph Walter of 200000 shares of Abeona Therapeutics subject to Rule 16b-3
Omalley Brendan M over six months ago via Macroaxis 
Sale by Omalley Brendan M of 8880 shares of Abeona Therapeutics
Omalley Brendan M over six months ago via Macroaxis 
Sale by Omalley Brendan M of 8880 shares of Abeona Therapeutics
Seshadri Vishwas over six months ago via Macroaxis 
Acquisition by Seshadri Vishwas of 300000 shares of Abeona Therapeutics subject to Rule 16b-3
Omalley Brendan M over six months ago via Macroaxis 
Sale by Omalley Brendan M of 25734 shares of Abeona Therapeutics
Omalley Brendan M over six months ago via Macroaxis 
Sale by Omalley Brendan M of 22763 shares of Abeona Therapeutics

Abeona Therapeutics Technical and Predictive Indicators

Abeona Therapeutics Forecast Models

Abeona Therapeutics time-series forecasting models is one of many Abeona Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Abeona Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Abeona Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Abeona Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Abeona shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Abeona Therapeutics. By using and applying Abeona Stock analysis, traders can create a robust methodology for identifying Abeona entry and exit points for their positions.
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York. Abeona Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 90 people.

Current Abeona Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Abeona analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Abeona analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
3.0Buy3Odds
Abeona Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Abeona analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Abeona stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Abeona Therapeutics, talking to its executives and customers, or listening to Abeona conference calls.
Abeona Analyst Advice Details

Abeona Stock Analysis Indicators

Abeona Therapeutics stock analysis indicators help investors evaluate how Abeona Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Abeona Therapeutics shares will generate the highest return on investment. By understating and applying Abeona Therapeutics stock analysis, traders can identify Abeona Therapeutics position entry and exit signals to maximize returns.
Quick Ratio2.54
Fifty Two Week Low0.2700
Shares Short Prior Month202.98k
Average Daily Volume Last 10 Day90.03k
Average Daily Volume In Three Month184.17k
Shares Percent Shares Out3.63%
Gross Margins24.81%
Short Percent Of Float3.67%
Forward Price Earnings-1.19
Float Shares4.95M
Fifty Two Week High29.5000
Enterprise Value To Ebitda-0.02
Fifty Day Average4.0710
Two Hundred Day Average5.7045
Enterprise Value To Revenue0.32
Please continue to Trending Equities. Note that the Abeona Therapeutics information on this page should be used as a complementary analysis to other Abeona Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Complementary Tools for Abeona Stock analysis

When running Abeona Therapeutics price analysis, check to measure Abeona Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abeona Therapeutics is operating at the current time. Most of Abeona Therapeutics' value examination focuses on studying past and present price action to predict the probability of Abeona Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Abeona Therapeutics' price. Additionally, you may evaluate how the addition of Abeona Therapeutics to your portfolios can decrease your overall portfolio volatility.
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Is Abeona Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abeona Therapeutics. If investors know Abeona will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abeona Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Abeona Therapeutics is measured differently than its book value, which is the value of Abeona that is recorded on the company's balance sheet. Investors also form their own opinion of Abeona Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Abeona Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abeona Therapeutics' market value can be influenced by many factors that don't directly affect Abeona Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abeona Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Abeona Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abeona Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.